Aptose Biosciences Inc. has announced the initiation of patient dosing in its TUSCANY Phase 1/2 study, which is investigating a new triplet therapy combining tuspetinib, venetoclax, and azacitidine ...
SAN DIEGO and TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results